



## ISSUE 6

**We are CMEL!** Welcome to the sixth issue of the CMEL Newsletter! This publication aims to update you on the latest news and information in the biomedical world. We will also share information about upcoming events, so stay tuned! Find out more about [CMEL](#). We also have a Facebook page, you can follow us [here](#).

## Top stories in this newsletter

### Conference on Compulsory Treatment



Compulsory Mental Health Treatment  
in Hong Kong: Which Way Forward?  
A two-day conference on the outstanding issue of mental  
health policy and human rights  
25-26 AUG 2017  
Large Meet Court, 2/F, Faculty of Law, Cheng Yu Tung Tower,  
Centennial Campus, The University of Hong Kong

Our two-day conference, “Compulsory Mental Health Treatment in Hong Kong: Which Way Forward?” was successfully completed. We would like to thank all of those who came and/or contributed to the many interesting discussions we had. Please click [here](#) to access our speakers’ presentations and photos of the event.

為期兩天的「香港強制精神科治療：何去何從？」會議已經完滿結束。本中心衷心感謝各位來賓的參與。如希望觀看講者簡佈或活動照片請[按此](#)。

Further information 相關資料：  
[Q&A about the proceedings of the conference](#)  
[法律學者倡改強制入院制 增保障精神病患者](#)

### In the News: Hyper-resistant, hypervirulent superbug discovered



Scientists in Hong Kong and China have discovered a transmissible, hyper-resistant and hypervirulent “superbug” bacteria that can lead to fatal infections and pose a significant threat to the wider public health. The bacteria caused the death of five patients who underwent surgery of multiple-trauma in China last year. Read more [here](#).

中港兩地研究人員在內地發現一種具高抗藥性，高致病性，並無藥可治的新型肺炎克雷伯菌。該致命的超級細菌有可能廣泛威脅中國甚或全球的公共衛生。該菌去年導致 5 名 進行外科手術後感染嚴重肺炎的內地患者死亡。詳情請[按此](#)。

### Commentary: FDA approves first gene therapy



The Food and Drug Administration of the United States have recently approved Kymriah, the first gene therapy for sale. This therapy, which targets sufferers of childhood leukaemia, alters patients’ cells to attack the disease. Despite the historic nature of this approval, Kymriah continues to face difficulties such as its life-threatening side effects and high costs. It is argued, therefore, that this is only the beginning of a long road towards common application of gene therapy. Press [here](#) to read more.

美國食品和藥物管理局為創新的醫療方法 Kymriah 發出許可認證。Kymriah 能把兒童白血病人的細胞改造去對抗該疾病，並成為首個獲許可出售的基因治療。然而，Kymriah 仍然面臨其他問題，比如嚴重副作用和其高成本等。因此，評論認為這次的許可認證只是基因治療發展和普及化的起步。有關評論詳情請[按此](#)。

### Upcoming Conference: Tackling Antimicrobial Resistance: Meeting the Global Challenge of AMR



Don’t miss our upcoming conference on the highly important issue of antimicrobial resistance! The two-day conference will be held on 9-10 November, and will include presentations from eminent speakers all over the world. Find out more information and register [here](#).

本中心十一月將舉行有關抗微生物藥物耐藥性的國際研討會，現接受登記。屆時來自世界各地的專家將就這議題作出多方面的探討和議論。詳情及報名請[按此](#)。